Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension
Lacuna Pharma Pty Ltd
Non-Cystic Fibrosis Bronchiectasis
1 trial -
Timolol Micro Labs 5 mg/ml Augentropfen, Losung, Zink Verla® 10 mg, Filmtabletten, Doxy-M-ratiopharm 100 mg tabletės, Protopic 0.1% ointment, ClobeGalen 500 Mikrogramm/g Shampoo, JNJ-73841937, Dociton® 10 mg Filmtabletten, Doxy-M-ratiopharm® 100 mg Tabletten, JNJ-61186372, MINOCIN 50 mg capsule rigide, Minocyclin-ratiopharm® 100 mg Hartkapseln, Protopic 0.1% ointment, Timolol 0,5 % AT - 1 A Pharma, 5 mg/ml Augentropfen, Lösung, Doxyderma 50 mg, Opzelura 15 mg/g cream, JNJ-61186372, Chlorhexidine, Dalacin 10
Janssen-Cilag International N.V.
EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
Topical endoxifen
ATOSSA THERAPEUTICS, INC.
Mammographic Breast Density
1 trial -
Tovorafenib, Tovorafenib
AXIM BIOTECHNOLOGIES, INC.
craniopharyngioma
1 trial -
Tovorafenib, Tovorafenib
Lacuna Pharma Pty Ltd
RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients
1 trial -
VAY736, ARTICAINE, COMBINATIONS, TENOFOVIR ALAFENAMIDE, PERFLUTREN, PHOSPHOLIPID MICROSPHERES, ENTECAVIR , -
Novartis Pharmaceuticals
Sjögren's syndrome
1 trial -
VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL
Novartis Pharmaceuticals
Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus
1 trial -
Verzenios 50 mg film-coated tablets, TAMOXIFEN
Eli Lilly Co.
Metastatic Breast Cancer
1 trial -
Z-Endoxifen
ATOSSA THERAPEUTICS, INC.
Breast Density
1 trial -
Zelboraf 240 mg film-coated tablets
Ningbo Cancer Hospital
Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment
1 trial -
compound diclofenac sodium
The First People's Hospital of Lianyungang
Acute Abdominal Pain
1 trial -
dabrafenib
GlaxoSmithKline
Solid Tumours
1 trial -
emtricitabine/tenofovir alafenamide
United Therapeutics Europe Ltd
Acceptability of Health Care
1 trial -
iv ibuprofen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extremely Premature Infants
1 trial -
1 Nalmefene implant
BRIGHT MINDS BIOSCIENCES INC.
Opioid Abuse and Addiction
1 trial -
A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma
Oncopeptides AB (publ)
Recurrent glioblastoma
1 trial -
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
ATAFENOVIR 200 MG KAPSUL
BRIGHT MINDS BIOSCIENCES INC.
Bioequivalence
1 trial -
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.
Lacuna Pharma Pty Ltd
Rheumatoid arthritis, ulcerative colitis, atopic dermatitis, Crohn's disease, psoriatic arthritis, axial spondyloarthritis
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.
Lacuna Pharma Pty Ltd
Axial spondyloarthritis, Crohn’s disease, Ulcerative colitis, Atopic dermatitis, Rheumatoid arthritis, Psoriatic arthritis
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
An open-label, prospective, randomised, cross-over trial to assess the pharmacokinetics of an amorphous formulation of sorafenib in mesoporous magnesium carbonate (DPH001) compared to Nexavar® (sorafenib) in healthy volunteers
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources